Back to top
more

Evolus (EOLS)

(Delayed Data from NSDQ)

$13.24 USD

13.24
400,714

+0.47 (3.68%)

Updated May 15, 2024 04:00 PM ET

After-Market: $13.23 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (145 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for EOLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Evolus, Inc. [EOLS]

Reports for Purchase

Showing records 21 - 40 ( 51 total )

Company: Evolus, Inc.

Industry: Medical - Products

Record: 21

11/03/2021

Company Report

Pages: 6

Solid Quarter Bolstered by Strong Aesthetics Market; Reiterate Buy, Lower PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 22

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for EOLS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 23

08/05/2021

Company Report

Pages: 4

Growth in First Unencumbered Quarter as Evolus Looks to Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 24

05/13/2021

Company Report

Pages: 4

Returning to Where We Left Off Before the ITC and COVID; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 25

04/08/2021

Company Report

Pages: 5

Government Stimulus Should Stimulate Demand for Jeuveau

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 26

03/25/2021

Company Report

Pages: 5

Evolus Looks to the Future on 4Q Call; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 27

03/24/2021

Company Report

Pages: 4

ITC Dust Finally Settles with Daewoong Transactions Bolstering Balance Sheet; Reiterate Buy; PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 28

02/24/2021

Company Report

Pages: 4

Jeuveau Set for Growth With ITC in Rear View Mirror; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 29

02/22/2021

Company Report

Pages: 5

Cloud of Uncertainty Clears as Evolus Settles with AbbVie and Medytox, Ending Jeuveau IP Dispute; Reit Buy, PT to $18

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 30

01/27/2021

Industry Report

Pages: 15

2021 Roadmap of Key Events Across Our Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 31

12/17/2020

Company Report

Pages: 4

Down But Not Out: ITC Bans Jeuveau Import for 21 Months But Settlement Seems Likely; Reiterate Buy, Lower PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 32

10/30/2020

Company Report

Pages: 4

Jeuveau Shows Resilience, All Eyes on ITC Case; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 33

08/11/2020

Company Report

Pages: 5

Jeuveau Beats Expectations Showing Resilience in the Face of COVID-19; Reiterate Buy, Raise PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 34

07/07/2020

Company Report

Pages: 5

Initial ITC Ruling Against Evolus; Reiterate Buy But Lowering PT to $7 from $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 35

05/12/2020

Company Report

Pages: 6

1Q Not Surprisingly Noisy, But Company Remains Well Positioned for Long-Term Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 36

04/20/2020

Company Report

Pages: 6

Reshaping for Covid-19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 37

03/27/2020

Company Report

Pages: 6

Social Distancing Takes a Toll; Lower Estimates and PT Goes to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 38

02/26/2020

Company Report

Pages: 5

Launch Moves to Next Stage, Still on Track to Achieve #2 Position; Tweak Target to $31, Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 39

02/20/2020

Company Report

Pages: 5

Launch Remains Strong, Though ITC Overhang Persists; Tweak Target to $34, Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Evolus, Inc.

Industry: Medical - Products

Record: 40

01/10/2020

Daily Note

Pages: 3

Jeuveau Maintains Momentum to Close ''19; Stage Set for Strong 2020

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party